Which cancer patients are at higher risk of severe Covid-19

Recently, Journal of Clinical Oncology published a noteworthy study identifying which cancer patients have a higher risk of severe COVID-19. According to the study, cancer patients with more comorbidities, older patients, those who recently received cytotoxic treatment (such as chemotherapy), males and those with hematological malignancies (cancers originating in the blood and bone marrow) have a higher risk of COVID-19 mortality (loss of life). Vaccination is therefore particularly important for older cancer patients.
The study is based on data from the National COVID Cohort Collaborative (N3C), a large COVID-19 case and control group across the United States. The analysis included adults from the N3C group who had received a positive or negative COVID-19 diagnostic result between January 1, 2020 and March 25, 2021. The researchers aimed to examine potential risk factors for COVID-19 mortality (loss of life) in a subgroup of patients with cancer from this group.
Of a total of 4,382,085 patients in N3C, 38,614 patients with cancer and a COVID-19 diagnosis met the inclusion criteria for evaluation. The most common cancers among these patients were skin, breast, prostate and gastrointestinal cancers and hematological malignancies.
The presence of COVID-19 was associated with higher all-cause mortality in patients with cancer (hazard ratio, 1.20; 95% CI, 1.15-1.24; P <.001). Factors associated with this increased risk were a higher adjusted Charlson Comorbidity Index (comorbidity) score, age 65 and older, recent cytotoxic treatment, multiple tumor sites, male sex, hematological malignancy and residence in the southern or western United States.
In contrast to cytotoxic treatment (chemotherapy), recent use of immunotherapies or targeted therapies was not associated with increased mortality.
The study researchers noted that their findings regarding age, sex and comorbidities were consistent with previous research. In conclusion, future studies of this group of more than 4 million Covid-19 patients will provide more and more information about the evolving impact of COVID-19 on patients with cancer and additional evidence to guide the clinical management of this patient group.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.